Characteristics of patients with MM who were treated with ide-cel CAR-T therapy
| Patient characteristics . | Total cohort (N = 33) . |
|---|---|
| Age, y | |
| Median (range) | 62 (56-67) |
| >65, n (%) | 10 (30.3) |
| Gender, n (%) | |
| Female | 10 (30.3) |
| Male | 23 (69.7) |
| Race, n (%) | |
| White | 24 (72.7) |
| Black | 7 (21.2) |
| Other | 2 (6.1) |
| Diagnosis, n (%) | |
| CR | 9 (27.2) |
| VGPR | 5 (15.2) |
| PR | 5 (15.2) |
| ECOG performance score, n (%) | |
| 0-1 | 24 (72.7) |
| ≥2 | 4 (12.1) |
| Unknown | 5 (15.1) |
| Extramedullary disease, n (%) | |
| No | 20 (60) |
| Yes | 13 (40) |
| Previous lines of therapy, n (%) | |
| 3-4 | 6 (18) |
| 5-6 | 10 (30) |
| >6 | 17 (52) |
| Autologous stem cell transplantation history (yes or no), n (%) | |
| Yes | 30 (90.91) |
| No | 3 (9.09) |
| Bridging therapy (yes or no), n (%) | |
| Yes | 26 (79) |
| No | 7 (21) |
| R-ISS staging at CAR-T infusion, n (%) | |
| I | 5 (15) |
| II | 16 (49) |
| III | 12 (36) |
| Patient characteristics . | Total cohort (N = 33) . |
|---|---|
| Age, y | |
| Median (range) | 62 (56-67) |
| >65, n (%) | 10 (30.3) |
| Gender, n (%) | |
| Female | 10 (30.3) |
| Male | 23 (69.7) |
| Race, n (%) | |
| White | 24 (72.7) |
| Black | 7 (21.2) |
| Other | 2 (6.1) |
| Diagnosis, n (%) | |
| CR | 9 (27.2) |
| VGPR | 5 (15.2) |
| PR | 5 (15.2) |
| ECOG performance score, n (%) | |
| 0-1 | 24 (72.7) |
| ≥2 | 4 (12.1) |
| Unknown | 5 (15.1) |
| Extramedullary disease, n (%) | |
| No | 20 (60) |
| Yes | 13 (40) |
| Previous lines of therapy, n (%) | |
| 3-4 | 6 (18) |
| 5-6 | 10 (30) |
| >6 | 17 (52) |
| Autologous stem cell transplantation history (yes or no), n (%) | |
| Yes | 30 (90.91) |
| No | 3 (9.09) |
| Bridging therapy (yes or no), n (%) | |
| Yes | 26 (79) |
| No | 7 (21) |
| R-ISS staging at CAR-T infusion, n (%) | |
| I | 5 (15) |
| II | 16 (49) |
| III | 12 (36) |
ECOG, Eastern Cooperative Oncology Group; R-ISS, Revised International Staging System.